BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BMS-986525 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BMS-986525\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07325136-11180@assetmemo.bio
DTSTAMP:20261121T005434Z
DTSTART;VALUE=DATE:20290423
DTEND;VALUE=DATE:20290424
SUMMARY:BMS-986525: Phase 1/2 readout est. (NCT07325136)
DESCRIPTION:BMS-986525\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Stud
 y to Assess the Safety and Tolerability of BMS-986525 Alone and in Combina
 tion Therapy in Participants With Relapsed/Refractory Small Cell Lung Canc
 er\nEstimated primary completion: 23 April 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/bms-986525#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07325136
URL:https://assetmemo.bio/drug/bms-986525#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
